Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

In its first-quarter 2025 investor letter, RiverPark Large Growth Fund highlighted stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may earn compensation through affiliate links within the story. All prices are ...

Actress Evangeline Lilly shared photos of the gruesome injuries she sustained after fainting. Actress Evangeline Lilly shared photos of the gruesome injuries she sustained after fainting.

Marvel star Evangeline Lilly has revealed an image of her wounded face, recounting that she had a "hole punctured into my face" after she fainted and "fell face first into a boulder". In an ...

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics ...

Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes SiteOne's STC-004 ...

(RTTNews) - Eli Lilly and Company (LLY), Tuesday announced an agreement regarding the acquisition of SiteOne Therapeutics, Inc., a private biotechnology company, for upto $1 billion in cash ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has penned a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to ...

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of ...